Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results, Misses Estimates By $0.65 EPS

Arrowhead Pharmaceuticals (NASDAQ:ARWR) released its quarterly earnings data on Monday. The biotechnology company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.65), MarketWatch Earnings reports. Arrowhead Pharmaceuticals had a negative return on equity of 28.00% and a negative net margin of 116.97%. During the same quarter in the prior year, the company earned ($0.48) earnings per share.

Shares of ARWR stock traded up $0.36 on Wednesday, hitting $71.25. 1,609 shares of the company’s stock traded hands, compared to its average volume of 742,274. Arrowhead Pharmaceuticals has a one year low of $56.05 and a one year high of $93.66. The company’s fifty day simple moving average is $66.91 and its 200 day simple moving average is $69.40. The stock has a market capitalization of $7.43 billion, a price-to-earnings ratio of -57.63 and a beta of 1.14.

In other Arrowhead Pharmaceuticals news, insider Martin Javier San sold 19,500 shares of the firm’s stock in a transaction on Friday, November 19th. The shares were sold at an average price of $69.31, for a total value of $1,351,545.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Adeoye Y. Olukotun sold 5,000 shares of the firm’s stock in a transaction on Monday, September 13th. The stock was sold at an average price of $63.76, for a total transaction of $318,800.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 89,500 shares of company stock worth $5,945,295. 3.50% of the stock is owned by insiders.

A hedge fund recently raised its stake in Arrowhead Pharmaceuticals stock. LPL Financial LLC grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 100.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,116 shares of the biotechnology company’s stock after purchasing an additional 9,579 shares during the period. LPL Financial LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,193,000 as of its most recent SEC filing. Institutional investors own 63.54% of the company’s stock.

Several research firms recently commented on ARWR. Chardan Capital cut their price objective on shares of Arrowhead Pharmaceuticals from $97.00 to $94.00 and set a “buy” rating for the company in a report on Friday, August 6th. TheStreet raised shares of Arrowhead Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Thursday, November 4th. SVB Leerink raised their price objective on shares of Arrowhead Pharmaceuticals from $44.00 to $45.00 and gave the stock a “market perform” rating in a report on Tuesday. Finally, HC Wainwright raised their price objective on shares of Arrowhead Pharmaceuticals from $95.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, August 10th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $88.09.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R.

Featured Story: Most Active Stocks: Dollar Volume vs Share Volume

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.